Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386910367> ?p ?o ?g. }
- W4386910367 abstract "Germline gene panel testing is recommended for men with advanced prostate cancer (PCa) or a family history of cancer. While evidence is limited for some genes currently included in panel testing, gene panels are also likely to be incomplete and missing genes that influence PCa risk and aggressive disease.To identify genes associated with aggressive PCa.A 2-stage exome sequencing case-only genetic association study was conducted including men of European ancestry from 18 international studies. Data analysis was performed from January 2021 to March 2023. Participants were 9185 men with aggressive PCa (including 6033 who died of PCa and 2397 with confirmed metastasis) and 8361 men with nonaggressive PCa.Sequencing data were evaluated exome-wide and in a focused investigation of 29 DNA repair pathway and cancer susceptibility genes, many of which are included on gene panels.The primary study outcomes were aggressive (category T4 or both T3 and Gleason score ≥8 tumors, metastatic PCa, or PCa death) vs nonaggressive PCa (category T1 or T2 and Gleason score ≤6 tumors without known recurrence), and metastatic vs nonaggressive PCa.A total of 17 546 men of European ancestry were included in the analyses; mean (SD) age at diagnosis was 65.1 (9.2) years in patients with aggressive PCa and 63.7 (8.0) years in those with nonaggressive disease. The strongest evidence of association with aggressive or metastatic PCa was noted for rare deleterious variants in known PCa risk genes BRCA2 and ATM (P ≤ 1.9 × 10-6), followed by NBN (P = 1.7 × 10-4). This study found nominal evidence (P < .05) of association with rare deleterious variants in MSH2, XRCC2, and MRE11A. Five other genes had evidence of greater risk (OR≥2) but carrier frequency differences between aggressive and nonaggressive PCa were not statistically significant: TP53, RAD51D, BARD1, GEN1, and SLX4. Deleterious variants in these 11 candidate genes were carried by 2.3% of patients with nonaggressive, 5.6% with aggressive, and 7.0% with metastatic PCa.The findings of this study provide further support for DNA repair and cancer susceptibility genes to better inform disease management in men with PCa and for extending testing to men with nonaggressive disease, as men carrying deleterious alleles in these genes are likely to develop more advanced disease." @default.
- W4386910367 created "2023-09-22" @default.
- W4386910367 creator A5007768066 @default.
- W4386910367 creator A5008093775 @default.
- W4386910367 creator A5014422690 @default.
- W4386910367 creator A5015244902 @default.
- W4386910367 creator A5015603316 @default.
- W4386910367 creator A5015974298 @default.
- W4386910367 creator A5016908886 @default.
- W4386910367 creator A5018863416 @default.
- W4386910367 creator A5019133187 @default.
- W4386910367 creator A5022311881 @default.
- W4386910367 creator A5025926870 @default.
- W4386910367 creator A5027914604 @default.
- W4386910367 creator A5031594786 @default.
- W4386910367 creator A5033064438 @default.
- W4386910367 creator A5033702527 @default.
- W4386910367 creator A5038304154 @default.
- W4386910367 creator A5039379417 @default.
- W4386910367 creator A5040933938 @default.
- W4386910367 creator A5043794455 @default.
- W4386910367 creator A5044923844 @default.
- W4386910367 creator A5049518334 @default.
- W4386910367 creator A5049753330 @default.
- W4386910367 creator A5051110113 @default.
- W4386910367 creator A5051694041 @default.
- W4386910367 creator A5056041412 @default.
- W4386910367 creator A5061697748 @default.
- W4386910367 creator A5063459619 @default.
- W4386910367 creator A5064313967 @default.
- W4386910367 creator A5064811251 @default.
- W4386910367 creator A5064882006 @default.
- W4386910367 creator A5065869555 @default.
- W4386910367 creator A5066045984 @default.
- W4386910367 creator A5066410308 @default.
- W4386910367 creator A5067052917 @default.
- W4386910367 creator A5071499564 @default.
- W4386910367 creator A5074874979 @default.
- W4386910367 creator A5087152170 @default.
- W4386910367 date "2023-09-21" @default.
- W4386910367 modified "2023-10-18" @default.
- W4386910367 title "Germline Sequencing Analysis to Inform Clinical Gene Panel Testing for Aggressive Prostate Cancer" @default.
- W4386910367 cites W1779829992 @default.
- W4386910367 cites W2003826324 @default.
- W4386910367 cites W2012071848 @default.
- W4386910367 cites W2032346580 @default.
- W4386910367 cites W2043051674 @default.
- W4386910367 cites W2059057685 @default.
- W4386910367 cites W2078485114 @default.
- W4386910367 cites W2079185082 @default.
- W4386910367 cites W2081722502 @default.
- W4386910367 cites W2110017381 @default.
- W4386910367 cites W2111437716 @default.
- W4386910367 cites W2126668914 @default.
- W4386910367 cites W2134785517 @default.
- W4386910367 cites W2145606954 @default.
- W4386910367 cites W2152054208 @default.
- W4386910367 cites W2154866190 @default.
- W4386910367 cites W2169058431 @default.
- W4386910367 cites W2235405584 @default.
- W4386910367 cites W2337895764 @default.
- W4386910367 cites W2338206828 @default.
- W4386910367 cites W2417483443 @default.
- W4386910367 cites W2462985846 @default.
- W4386910367 cites W2521967673 @default.
- W4386910367 cites W2567290427 @default.
- W4386910367 cites W2585524114 @default.
- W4386910367 cites W2621271973 @default.
- W4386910367 cites W2787607836 @default.
- W4386910367 cites W2808127389 @default.
- W4386910367 cites W2907554925 @default.
- W4386910367 cites W2911357089 @default.
- W4386910367 cites W2945522282 @default.
- W4386910367 cites W2962886430 @default.
- W4386910367 cites W3000265159 @default.
- W4386910367 cites W3003926749 @default.
- W4386910367 cites W3020771563 @default.
- W4386910367 cites W3026602570 @default.
- W4386910367 cites W3033920919 @default.
- W4386910367 cites W3082090251 @default.
- W4386910367 cites W3089370511 @default.
- W4386910367 cites W3121058498 @default.
- W4386910367 cites W3165576985 @default.
- W4386910367 cites W3207368269 @default.
- W4386910367 cites W3217349935 @default.
- W4386910367 cites W4212985089 @default.
- W4386910367 cites W4226265398 @default.
- W4386910367 cites W4253273778 @default.
- W4386910367 cites W4253276992 @default.
- W4386910367 cites W4283748697 @default.
- W4386910367 doi "https://doi.org/10.1001/jamaoncol.2023.3482" @default.
- W4386910367 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37733366" @default.
- W4386910367 hasPublicationYear "2023" @default.
- W4386910367 type Work @default.
- W4386910367 citedByCount "0" @default.
- W4386910367 crossrefType "journal-article" @default.
- W4386910367 hasAuthorship W4386910367A5007768066 @default.
- W4386910367 hasAuthorship W4386910367A5008093775 @default.
- W4386910367 hasAuthorship W4386910367A5014422690 @default.
- W4386910367 hasAuthorship W4386910367A5015244902 @default.